What development phase is SERDEXMETHYLPHENIDATE CHLORIDE in?

SERDEXMETHYLPHENIDATE CHLORIDE is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

SERDEXMETHYLPHENIDATE CHLORIDE

FDA-approved approved Small molecule Quality 0/100

Serdexmethylphenidate chloride is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, supported by its current revenue generation. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	SERDEXMETHYLPHENIDATE CHLORIDE
Modality	Small molecule
Phase	FDA-approved
First approval	2021

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD (PHASE3)
KP415 Classroom Study in Children (6-12 Years of Age) With ADHD (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results